Assessment of Silent Brain Injury in Chronic Total Occlusion Patients With Percutaneous Coronary Intervention
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Silent Stroke
- Sponsor
- Ondokuz Mayıs University
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Baseline Neuron-specific Enolase (NSE) measurement
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
This study examines the formation mechanism and patient-related factors of silent cerebral infarcts, whose importance has become increasingly recognized in patients undergoing percutaneous coronary intervention.
Detailed Description
This study was produced from the assistant's thesis and was previously accepted as a poster at EuroPCR 2020. We recently completed the full-length article. This thesis study was supported by Ondokuzmayis University.
Investigators
Muhammet Uyanik
Principal Investigator
Ondokuz Mayıs University
Eligibility Criteria
Inclusion Criteria
- •CTO and Non-CTO patients undergoing percutaneous coronary intervention
Exclusion Criteria
- •baseline NSE elevation
- •acute coronary syndromes or cardiac surgery within 4 weeks
- •patients with a cerebrovascular accident
- •intracranial hemorrhage
- •and head trauma
- •central nervous system tumor
- •degenerative central nervous system disorders and neuroendocrine tumors
Outcomes
Primary Outcomes
Baseline Neuron-specific Enolase (NSE) measurement
Time Frame: NSE blood levels were measured 1-2 hours before the procedure.
Baseline NSE measurement to exclude non-PCI dependent brain injury. Elevation of \>20 ng/ml was considered as silent brain injury. Patients with basal nse elevation were considered as SBI and excluded from the study.
Silent Brain Injury diagnosis
Time Frame: 12-18 hours after percutaneous coronary intervention
NSE blood levels were measured 12-18 hours after the procedure. Elevation of \>20 ng/ml was considered as SBI.